Table 3.
Univariate predictors of outcome
| 2yr NNLRC | NNLRC p-value | 2yr NC | NC p-value | 2yr DMF | DMF p-value | 2yr DFS | DFS p-value | ||
|---|---|---|---|---|---|---|---|---|---|
| Sex | |||||||||
| Female | 92% | 0.09 | 85% | 0.51 | 85% | 0.75 | 75% | 0.66 | |
| Male | 85% | 80% | 86% | 72% | |||||
| Age, yrs | |||||||||
| <65 | 89% | 0.26 | 88% | 0.08 | 94% | 0.02 | 83% | <0.005 | |
| ≥65 | 87% | 76% | 79% | 64% | |||||
| Primary site | |||||||||
| Head & neck | 86% | 0.26 | 79% | 0.73 | 76% | 0.21 | 67% | 0.54 | |
| Trunk/extremity | 88% | 82% | 88% | 75% | |||||
| Breslow thickness | |||||||||
| <4 mm | 91% | 0.02 | 85% | 0.019 | 88% | 0.022 | 78% | <0.005 | |
| >4 mm | 80% | 76% | 78% | 60% | |||||
| Microsatellites | |||||||||
| Absent | 92% | <0.005 | 85% | <0.005 | 86% | 0.34 | 78% | <0.005 | |
| Present | 60% | 92% | 85% | 39% | |||||
| Ulceration | |||||||||
| Absent | 90% | 0.19 | 85% | 0.012 | 88% | 0.02 | 79% | <0.005 | |
| Present | 84% | 77% | 82% | 64% | |||||
| PNI | |||||||||
| Absent | 89% | 0.28 | 81% | 0.93 | 85% | 0.11 | 74% | 0.019 | |
| Present | 83% | 84% | 86% | 67% | |||||
| LVI | |||||||||
| Absent | 93% | <0.005 | 91% | <0.005 | 89% | 0.01 | 83% | <0.005 | |
| Present | 77% | 60% | 79% | 53% | |||||
| ≥20 mitoses/mm2 | |||||||||
| No | 90% | <0.005 | 83% | 0.069 | 86% | 0.49 | 75% | 0.04 | |
| Yes | 69% | 69% | 79% | 57% | |||||
| >1 mm nodal deposit | |||||||||
| No | 89% | 0.61 | 91% | <0.005 | 94% | <0.005 | 84% | <0.005 | |
| Yes | 87% | 72% | 77% | 62% | |||||
| ≥2 lymph nodes positive | |||||||||
| No | 88% | 0.99 | 85% | 0.008 | 91% | <0.005 | 79% | <0.005 | |
| Yes | 89% | 71% | 70% | 57% | |||||
| Extracapsular extension | |||||||||
| No | 88% | 0.93 | 84% | 0.007 | 86% | <0.005 | 74% | <0.005 | |
| Yes | 89% | 61% | 78% | 61% | |||||
| AJCC 8e Stage | |||||||||
| IIIA | 94% | 0.1 | 94% | <0.005 | 96% | <0.005 | 91% | <0.005 | |
| IIIB-D | 85% | 75% | 80% | 63% | |||||
| Adjuvant systemic therapy | |||||||||
| No | 91% | 0.51 | 84% | 0.49 | 82% | 0.25 | 74% | 0.81 | |
| Yes | 85% | 80% | 89% | 72% | |||||
| Adjuvant immunotherapy | |||||||||
| No | 91% | 0.35 | 83% | 0.71 | 82% | 0.2 | 74% | 0.91 | |
| Yes | 84% | 81% | 90% | 73% | |||||
Abbreviations: DFS, disease-free survival, DMF, distant metastasis-free, LC, local control; LVI, lymphovascular invasion; NC, nodal control; NNLRC, non-nodal locoregional control (local and in-transit disease control); PNI, perineural invasion; yrs, years.